In a strategic move to bolster Europe’s 1st Dedicated DCT Site Network’s capabilities, expertise and footprint, FutureMeds has acquired CPS Research. This expansion promises to bring enhanced solutions to our clients and accelerated access to new treatments for our patients.
CPS Research, a community-based organisation renowned for its expertise in conducting clinical trials across phase II-IV trials, is now part of FutureMeds, Europe’s 1st Dedicated DCT Site Network.
Based in Glasgow, with reach across the central belt of Scotland, our site has over 30 years of clinical research experience. The CPS team has conducted over 250 studies across a wide range of therapeutic areas and indications, such as cardiology, endocrinology, gastroenterology, gynaecology, orthopaedics, psychiatry, immunology, dermatology, and respiratory medicine.
“The addition of CPS Research marks a significant milestone for our clients, volunteers and teams. CPS Research has a reputable standing in the industry, boasting over three decades of expertise overseeing and conducting clinical trials. We are thrilled to welcome their knowledgeable team into our fold.”
– John Allen, Managing Director at FutureMeds UK
With 16 years of experience in the Life Science industry, Craig McCallum will continue to lead the research team. His goal is to expand the team’s relationship with local communities, amplify the site’s impact in driving medical progress and improve patients’ access to new treatments.
“As we bring together our wealth of experience to the ultimate benefit of our clients and patients, we are truly excited for the future and what we will be able to achieve as part of such a growing powerhouse of medical research.”
– Craig McCallum, General Manager at CPS Research
CPS Research has established strong relationships with local GPs, vendors, and the life science community that enable us to boost recruitment, patient engagement and retention.
To further strengthen our reputation and offer additional benefits to patients, our medically and clinically qualified professional team works closely with universities, institutions, and local consultants to offer specialised services such as endoscopies, gynaecological procedures, and PK/PD-related services.
About the site in the heart of Glasgow
The site’s purpose-built facility sits on the edge of Glasgow City Centre, boasting excellent amenities & transport links and is trusted by patients.
CPS Research has over 4,000 engaged patients in the database, and with the FutureMeds DCT Toolkit, the catchment area can be extended over the Glasgow Urban area and the whole central Scotland belt with a population of approximately 3.6M.
CPS Research has full clinical and administrative facilities, including a fully equipped Clinical Unit containing six treatment rooms, restricted-access IMP/IP room, sample processing and storage with continuously monitored, ambient, 2-8°C, -20°C and -80°C controlled temperature units.
Legacy of CPS Research co-founders
The co-founders of CPS Research, Dr Alan Wade MBCHB FRCA and Dr Gordon Crawford BSC MBCHB MRCGP, will embark on a new chapter within a year. They have been instrumental in shaping the foundation and trajectory of the research site. Their commitment to elevating the Patient voice, pursuing medical progress, and driving trial design improvements will remain a lasting legacy.
“Having developed CPS Research with Alan, we are delighted to see it become part of the growing FutureMeds Site Network. By contributing to medical progress, we are sure CPS Research’s team will build on our legacy and continue to thrive as one of the best dedicated research centres in the UK.”
– Dr Gordon Crawford BSC MBCHB MRCGP, co-founder of CPS Research
Dr. Alan Wade embarked on an academic journey in anaesthesia before transitioning to General Practice. After dedicating two decades to this field, he chose to channel his passion into drug development. With a tenure of over 30 years, Alan has been at the forefront of designing innovative studies and refining protocols. His influential voice in the industry is further underscored by his over 100 peer-reviewed publications.
Dr. Gordon Crawford blended his role as a senior partner in a GP practice with his profound interest in pharmaceutical medicine. His dedication is evident in his role as the Principal Investigator in over a hundred clinical trials spanning diverse therapeutic areas. Gordon’s unique approach centres on amplifying the patient’s voice, aiming to ensure they play a pivotal role in the development and safety of new drugs and medical treatments.
The new chapter of CPS Research and FutureMeds
This acquisition marks a significant milestone for both companies, promising a brighter future for clinical research and the patient community in the country. The growing site network counts on CPS Research’s vast experience to further enhance FutureMeds’ site solutions, increase the impact of Site and Patient voice in the process of trial design and improve patient experience.
“After operating independently as an investigation site for a long time, we made the significant decision to join the FutureMeds team. We believe that partnering with a professional and dynamic organisation like FutureMeds is the best decision for our clients, patients, and employees.” added Craig.
About CPS Research
CPS Research has conducted over 250 studies over the course of their 30+ years of history. Their site specialises in phase II-IV trials for pharmaceuticals, microbiome therapies, OTC products, food supplements, and medical devices.
Besides conducting trials, CPS Research’s medically and clinically qualified management team provides consultancy services, with a track record of over 100 publications in their fields of expertise.
About FutureMeds
FutureMeds is the 1st European Dedicated DCT Site Network, offering high traditional trial and DCT readiness across the whole network and home nursing solutions in 16 countries.
FutureMeds’ Dedicated Research Site teams strive to accelerate study timelines, streamline processes, lower costs and improve data quality to help speed up drug development and patient access to new treatments.
Through acquisitions and a strategic focus on patient experience, FutureMeds has developed large, qualified patient pools across Europe that enable faster patient enrolment, stronger retention and more accurate results.
